ADVERTISEMENT
Press release content from Accesswire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Accesswire
Press release content from Accesswire. The AP news staff was not involved in its creation.

Novamind to Present at H.C. Wainwright 23rd Annual Global Investment Conference

September 8, 2021 GMT
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the ...
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the ...
TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the ...

TORONTO, ON / ACCESSWIRE / September 8, 2021 / Novamind Inc. (CSE:NM)(OTC PINK:NVMDF)(FSE:HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, is pleased to announce its participation in the H.C. Wainwright 23rd Annual Global Investment Conference (“the Conference”), taking place virtually on September 13-15, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present the Company’s business model focused on growing a national network of psychiatry clinics and clinical research sites to rapidly scale access to psychedelic medicine.

The corporate presentation will be available to registered Conference attendees for on-demand viewing beginning at 7:00 AM EST on September 13.

Qualified investors can learn more about the Conference and register to schedule a one-on-one meeting with Novamind’s management here.

ADVERTISEMENT

About Novamind

Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information

Novamind

Yaron Conforti, CEO and Director

Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications

Email: media@novamind.ca

Bill Mitoulas, Investor Relations

Email: bill@novamind.ca

Forward-Looking Statements

ADVERTISEMENT

This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

SOURCE: Novamind Inc.

View source version on accesswire.com:

https://www.accesswire.com/663128/Novamind-to-Present-at-HC-Wainwright-23rd-Annual-Global-Investment-Conference